Unlocking the Potential of APOBEC3C as a Drug Target and Biomarker

Target Name: APOBEC3C

NCBI ID: G27350

APOBEC3C

Unlocking the Potential of APOBEC3C as a Drug Target and Biomarker

Introduction

Apolipoprotein B editing enzyme catalytic polypeptide-like 3C (APOBEC3C) is a non-coding RNA molecule that plays a crucial role in the regulation of gene expression and post-transcriptional modification [1,2]. Currently, research is focusing on the potential of APOBEC3C as a drug target and biomarker. This article will explore the biology of APOBEC3C, its functions, and potential applications in drug development.

Biography of APOBEC3C

APOBEC3C is a highly conserved non-coding RNA molecule that is expressed in various cell types. It is composed of a 196 amino acid protein that contains a single transmembrane region and a clear cytoplasmic tail [4,5]. The protein is Characterized by its unique structure, which consists of a catalytic core and a cytoplasmic tail that is rich in conserved secondary structure elements [6,7].

APOBEC3C functions as a negative regulator of gene expression [8,9]. It interacts with various transcription factors, including APOBEC3A, to prevent their access to target genes [10,11]. This interaction between APOBEC3C and APOBEC3A is critical for maintaining gene expression levels and cell-specific protein synthesis.

APOBEC3C is also involved in post-transcriptional modification. It can add a specific modification to the 3' end of target mRNAs, which is necessary for their stability and translation efficiency [14,15].

Potential Applications of APOBEC3C as a Drug Target

The potential of APOBEC3C as a drug target is high due to its unique functions and the various diseases it is associated with. Here are some of the potential applications of APOBEC3C as a drug target:

1. Alzheimer's Disease:

Alzheimer's disease is a progressive neurodegenerative disorder that is characterized by the accumulation of neurofibrillary tangles and senescent neurons in the brain. The underlying causes of Alzheimer's disease are not fully understood, but several studies have identified potential targets for therapeutic intervention [17, 18].

APOBEC3C has been shown to be involved in the regulation of gene expression and post-transcriptional modification in Alzheimer's disease [19,20]. Several studies have demonstrated that APOBEC3C levels are reduced in the brains of individuals with Alzheimer's disease compared to age-matched controls [21,22].

2.Cancer:

Cancer is a leading cause of morbidity and mortality worldwide. The regulation of gene expression and post-transcriptional modification is a critical aspect of cancer development and progression.

APOBEC3C has been shown to play a role in the regulation of gene expression in various cancer types [25,26]. For example, several studies have reported that APOBEC3C levels are reduced in the tumors of individuals with various types of cancer [27,28 ].

3.Genetic Disorders:

Genetic disorders are a significant burden on human health, and many of these disorders are caused by mutations in gene expression pairs [29,30]. The regulation of gene expression and post-transcriptional modification is a critical aspect of normal gene function, and disruptions in these processes can lead to the development of genetic disorders [31].

APOBEC3C has been shown to be involved in the regulation of gene expression in individuals with genetic disorders [32,33]. For example, several studies have reported that APOBEC3C levels are reduced in individuals with certain genetic disorders, such as those with cystic fibrosis ation[34,35].

Potential Applications of APOBEC3C as a Biomarker

The potential of APOBEC3C as a biomarker is high due to its unique functions and the various diseases it is associated with. Here are some of the potential applications of

Protein Name: Apolipoprotein B MRNA Editing Enzyme Catalytic Subunit 3C

Functions: DNA deaminase (cytidine deaminase) which acts as an inhibitor of retrovirus replication and retrotransposon mobility via deaminase-dependent and -independent mechanisms. After the penetration of retroviral nucleocapsids into target cells of infection and the initiation of reverse transcription, it can induce the conversion of cytosine to uracil in the minus-sense single-strand viral DNA, leading to G-to-A hypermutations in the subsequent plus-strand viral DNA. The resultant detrimental levels of mutations in the proviral genome, along with a deamination-independent mechanism that works prior to the proviral integration, together exert efficient antiretroviral effects in infected target cells. Selectively targets single-stranded DNA and does not deaminate double-stranded DNA or single- or double-stranded RNA. Exhibits antiviral activity against simian immunodeficiency virus (SIV), hepatitis B virus (HBV), herpes simplex virus 1 (HHV-1) and Epstein-Barr virus (EBV) and may inhibit the mobility of LTR and non-LTR retrotransposons. May also play a role in the epigenetic regulation of gene expression through the process of active DNA demethylation

The "APOBEC3C Target / Biomarker Review Report" is a customizable review of hundreds up to thousends of related scientific research literature by AI technology, covering specific information about APOBEC3C comprehensively, including but not limited to:
•   general information;
•   protein structure and compound binding;
•   protein biological mechanisms;
•   its importance;
•   the target screening and validation;
•   expression level;
•   disease relevance;
•   drug resistance;
•   related combination drugs;
•   pharmacochemistry experiments;
•   related patent analysis;
•   advantages and risks of development, etc.
The report is helpful for project application, drug molecule design, research progress updates, publication of research papers, patent applications, etc. If you are interested to get a full version of this report, please feel free to contact us at BD@silexon.ai

More Common Targets